ClinicalTrialsFinder
RecruitingPhase 1Phase 2NCT07429253

Secretome vs. PRP Injections for Hair Density and Growth in Androgenetic Alopecia Patients

Comparative Effectiveness of Secretome Injection and Intradermal Platelet-Rich Plasma Injection on Hair Density and Terminal-to-Vellus Hair Ratio in Patients With Androgenetic Alopecia at Prof. Dr. I.G.N.G. Ngoerah General Hospital

Sponsor

PT. Prodia Stem Cell Indonesia

Enrollment

40 participants

Start Date

Jan 9, 2026

Study Type

INTERVENTIONAL

Summary

This study aims to compare the effectiveness of secretome injection and intradermal platelet-rich plasma (PRP) injection on hair density and the terminal-to-vellus hair ratio in patients with androgenetic alopecia at Prof. Dr. I.G.N.G. Ngoerah General Hospital.

Eligibility

Min Age: 25 YearsMax Age: 59 Years

Inclusion Criteria6

  • Male patients with androgenetic alopecia, aged 25 to 59 years, with clinical presentation consistent with Hamilton-Norwood grades II to VI, seeking treatment at the Dermatology and Venereology Outpatient Clinic of Prof. Dr. I.G.N.G. Ngoerah General Hospital.
  • Female patients with androgenetic alopecia, aged 25 to 59 years, with clinical presentation consistent with Ludwig grades I to III, seeking treatment at the Dermatology and Venereology Outpatient Clinic of Prof. Dr. I.G.N.G. Ngoerah General Hospital.
  • Female patients who are not currently pregnant or breastfeeding.
  • Patients who have discontinued anti-androgen medication and minoxidil for at least 1 month prior to the procedure.
  • Patients with no known allergies to secretome components and/or materials used in the platelet-rich plasma (PRP) preparation process.
  • Patients who are proficient in Indonesian and willing to provide written informed consent.

Exclusion Criteria8

  • Participants who are unable to speak or understand Indonesian and/or are unwilling to provide written informed consent.
  • Patients presenting with types of hair loss other than androgenetic alopecia.
  • Patients currently undergoing therapy with 5-alpha reductase inhibitors.
  • Patients who have received intradermal corticosteroid injections to the scalp within at least 6 months prior to the study.
  • Patients with active infections and/or active dermatitis on the scalp.
  • Patients with a known history of allergy to secretome components and/or materials used in the platelet-rich plasma (PRP) preparation process.
  • History of hypertrophic scarring or blood clotting (coagulation) disorders.
  • Patients unable to complete the research procedures in their entirety.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALSecretome

UC-MSC secretome was injected intradermally into the scalp at the alopecia site, with injections spaced 1 cm apart and administered every 2 weeks for 8 weeks

BIOLOGICALPlatelet-Rich Plasma (PRP) Injections

The centrifuged plasma solution was injected intradermally into the scalp at the alopecia site, with 0.1 ml per injection point spaced 1 cm apart, administered every 2 weeks for 8 weeks

Locations(1)

Prof. dr. I.G.N.G. Ngoerah Central General Hospital

Denpasar, Bali, Indonesia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07429253